LENSAR Inc (LNSR) — Titan Protect Analysis

LNSR

LENSAR Inc

Healthcare · ·

$5.60

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$69M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.07

Based on estimated future earnings — lower means cheaper

Rev Growth

-5.2%

Year-over-year revenue change

Profit Margin

50.9%

How much profit the company keeps from each dollar of revenue

ROE

362.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.50

+52% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About LENSAR Inc

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, de

https://www.lensar.com

Country: United States Employees: 150 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.453

Positive but modest risk-adjusted returns

Kelly Fraction

0.0119

Marginal edge — very small allocation suggested

Calmar Ratio

0.118

Drawdown risk outweighs the returns — higher risk profile

Annual Return

8.3%

Historical annualised return based on price data

Max Drawdown

-69.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.84

Less volatile than the market — more defensive

52W High

$13.67

59% below the year high

52W Low

$5.06

11% above the year low

Avg Volume

118,846

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.55

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.47

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

45.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

49.2%

Profit from core operations before interest and tax

Free Cash Flow

$-17,200,624

Negative — the business is spending more than it generates

Revenue (TTM)

$58M

Total revenue over the last 12 months

Net Income

$29M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$8.50

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go